Pembrolizumab

monoclonal antibody

Identifier: CI-DRUG-00000464
Entity page: /drug/pembrolizumab ↗
Edges: 2,956

Neighbours: 38 cancers1 genes12 variants10 trials113 approvals
Drawn: 60 of 174 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Pembrolizumab approved for …APPROVED_FOR152 of 113show fewer
→ approved for	Triple-Negative Breast Carcinomamolecular_subtype	supports	FDA ORIG	Triple-Negative Breast Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Endometrial Carcinomasubtype

→ approved for

EMA · EU · 2015Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non small cell lung carcinoma at high risk of recurrence in adults Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5.1). Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations. Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations. Keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. Keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA. Malignant pleural mesothelioma (MPM) Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma. Classical Hodgkin lymphoma (cHL) Keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. Urothelial carcinoma Keytruda, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adults with resectable muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin‑containing chemotherapy. Keytruda, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults. Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy.Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express PD L1 with a combined positive score (CPS) ≥ 10. Head and neck squamous cell carcinoma (HNSCC) Keytruda as monotherapy is indicated for the treatment of resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS ≥ 1. Keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 FU) chemotherapy, is indicated for the first line treatment of metastatic or unresectable …

EMA (EU) · approved · 2015-07-17 · Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectab…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

FDA · US · 2014for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. • Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. • Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. • in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. • in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. • for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. • Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 • Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. • Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. • 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

FDA (US) · approved · tumour-agnostic · 2014-09-04 · for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. • Limitations of Us…

—

approved

not mapped

Regulatory

openfda

open ↗

Pembrolizumab predicts response to …PREDICTS_RESPONSE_TO13 of 13
← predicts response to	CD274 Expressionexpression 6 source records aggregated	sensitivity	B	Lung Non-Small Cell Carcinoma,Melanoma	6	Curated	civic	graph →
← predicts response to	High 3 source records aggregated	sensitivity	B	Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm,Solid Neoplasm	3	Curated	civic	graph →
← predicts response to	DNMT3A Mutationother	resistance	B	Malignant Neoplasm	1	Curated	civic	graph →
← predicts response to	HLA-DRA EXPRESSIONexpression	sensitivity	B	Cutaneous Melanoma	1	Curated	civic	graph →
← predicts response to	STK11 Mutationother	resistance	B	Lung Adenocarcinoma	1	Curated	civic	graph →
← predicts response to	POLE Mutationother 2 source records aggregated	sensitivity	C	Glioblastoma,Malignant Endometrial Neoplasm	2	Curated	civic	graph →
← predicts response to	High	sensitivity	C	Adrenal Cortical Carcinoma	1	Curated	civic	graph →
← predicts response to	POLD1 E374KSNV	sensitivity	C	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	JAK2 Splice Site (c.1641+2T>G)splice	resistance	C	Melanoma	1	Curated	civic	graph →
← predicts response to	POLD1 C284YSNV	sensitivity	C	Lung Adenocarcinoma	1	Curated	civic	graph →
← predicts response to	B2M S14FSindel	resistance	C	Cutaneous Melanoma	1	Curated	civic	graph →
← predicts response to	JAK2 c.1641+1dup	resistance	C	Cutaneous Melanoma	1	Curated	civic	graph →
← predicts response to	JAK1 Q503*SNV	resistance	C	Cutaneous Melanoma	1	Curated	civic	graph →

Pembrolizumab investigated for …INVESTIGATED_FOR15 of 121show all (up to 200)
→ investigated for	Lung Non-Small Cell Carcinomasubtype 6 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	6	Curated	civic	graph →
→ investigated for	Malignant Colorectal Neoplasmsubtype	supports	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
→ investigated for	Malignant Neoplasmcancer_family	supports	B	Malignant Neoplasm	1	Curated	civic	graph →
→ investigated for	Cutaneous Melanomacancer	supports	B	Cutaneous Melanoma	1	Curated	civic	graph →
→ investigated for	Solid Neoplasmcancer_family	supports	B	Solid Neoplasm	1	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype	supports	B	Lung Adenocarcinoma	1	Curated	civic	graph →
→ investigated for	Melanomacancer_family	supports	B	Melanoma	1	Curated	civic	graph →
→ investigated for	Transitional Cell Carcinomahistology	unknown	4	Transitional Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype	unknown	4	Head and Neck Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Endometrial Neoplasmsubtype	unknown	4	Endometrial Neoplasm	1	Curated	chembl	graph →
→ investigated for	Hodgkin Lymphomahematologic_malignancy	unknown	4	Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Squamous Cell Carcinomahistology	unknown	4	Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Renal Cell Carcinomasubtype	unknown	4	Renal Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →

Pembrolizumab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 525show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 395 trials (181 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	395	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 229 trials (83 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	229	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasmcancer_family 179 trials (88 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	179	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinomasubtype 171 trials (81 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	171	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinomamolecular_subtype 137 trials (73 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	137	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 102 trials (46 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinomasubtype 94 trials (37 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	94	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasmcancer_family 89 trials (41 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	89	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 85 trials (45 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 82 trials (39 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	82	Observed	clinicaltrials	graph →
→ investigated in trials for	Urothelial Carcinomasubtype 72 trials (38 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Urothelial Carcinoma	72	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinomasubtype 61 trials (17 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	61	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasmcancer 59 trials (23 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	59	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasm 56 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 52 trials (22 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	52	Observed	clinicaltrials	graph →

Pembrolizumab studied in …STUDIED_INderived10 of 2,183show all (up to 200)
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · 2,183 trials list this drug (975 active)	—	—	Endocrine Neoplasm,Malignant Breast Neoplasm,Multiple Myeloma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03833167Phase 3 · terminated Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) · 2,183 trials list this drug (975 active)	—	—	Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03834493Phase 3 · terminated Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) · 2,183 trials list this drug (975 active)	—	—	Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03976323Phase 3 · completed Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) · 2,183 trials list this drug (975 active)	—	—	Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04191096Phase 3 · terminated Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) · 2,183 trials list this drug (975 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 2,183 trials list this drug (975 active)	—	—	Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 2,183 trials list this drug (975 active)	—	—	Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05562830Phase 1/Phase 2 · recruiting A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) · 2,183 trials list this drug (975 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05753722Phase 1 · completed A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies · 2,183 trials list this drug (975 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · 2,183 trials list this drug (975 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths